You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Zetia Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zetia patents expire, and what generic alternatives are available?

Zetia is a drug marketed by Organon and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-five patent family members in thirty-eight countries.

The generic ingredient in ZETIA is ezetimibe. There are twenty-four drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ezetimibe profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zetia

A generic version of Zetia was approved as ezetimibe by GLENMARK PHARMS LTD on June 26th, 2015.

  Try a Trial

Paragraph IV (Patent) Challenges for ZETIA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZETIA Tablets ezetimibe 10 mg 021445 1 2006-10-25

US Patents and Regulatory Information for Zetia

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Zetia

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 ⤷  Try a Trial ⤷  Try a Trial
Organon ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 ⤷  Try a Trial ⤷  Try a Trial
Organon ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 ⤷  Try a Trial ⤷  Try a Trial
Organon ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for Zetia

See the table below for patents covering Zetia around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2356550 КОМБИНАЦИИ АКТИВАТОРА (АКТИВАТОРОВ) РЕЦЕПТОРА, АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ (РАПП), И ИНГИБИТОРА (ИНГИБИТОРОВ) ВСАСЫВАНИЯ СТЕРИНА И ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ СОСУДОВ (COMBINED ACTIVATOR (ACTIVATORS) OF RECEPTOR ACTIVATED WITH PEROXISE PROLIFERATOR (RAPP), AND STEROL ABSORPTION INHIBITOR (INHIBITORS) AND TREATMENT OF VESSEL DISEASES) ⤷  Try a Trial
Czech Republic 301871 Kombinace aktivátoru receptoru, aktivovaného proliferátorem peroxisomu fenofibrátu s inhibitorem vstrebávání sterolu ezetimibem pro použití pri cévních chorobách (Combinations of peroxisome proliferator-activated receptor activator phenofibrate with sterol absorption inhibitor ezetimibe for use in the treatment of vascular diseases) ⤷  Try a Trial
Canada 2434504 ⤷  Try a Trial
China 1131416 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for Zetia

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 SPC/GB05/010 United Kingdom ⤷  Try a Trial PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
0720599 300688 Netherlands ⤷  Try a Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724
0720599 300132 Netherlands ⤷  Try a Trial 300132, 20140914, EXPIRES: 20171016
0720599 92544 Luxembourg ⤷  Try a Trial PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.